Tarceva Pancreatic Cancer Survival Benefit Is Small But Clinically Meaningful, Committee Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Tarceva (erlotinib) survival difference of two weeks to one month, depending on the analysis, is statistically persuasive, FDA’s Oncologic Drugs Advisory Committee says at Sept. 13 meeting.You may also be interested in...
From Avastin To Zevalin: ODAC’s Most Memorable Moments
The current and former leaders of FDA’s Oncologic Drugs Advisory Committee recount their most memorable moments of service on the panel.
Roche's Xeloda Shows Significant Survival Benefit In Pancreatic Cancer
Combo therapy of Xeloda plus gemcitabine shows median survival of 7.4 months versus six months with Gemzar alone.
FDA Approves Tarceva For Pancreatic Cancer
Supplemental NDA approval for Genentech/OSI’s erlotinib, previously approved for lung cancer, follows advisory committee recommendation.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: